ARGATROBAN IN DEXTROSE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARGATROBAN IN DEXTROSE (ARGATROBAN IN DEXTROSE).
Argatroban is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and protein C, and platelet aggregation.
| Metabolism | Hepatic metabolism primarily via hydroxylation and aromatization by CYP3A4/5 to four active metabolites with 3-5 times weaker anticoagulant activity than the parent drug. |
| Excretion | Primarily hepatobiliary (fecal excretion) ~65% as unchanged drug and metabolites; renal excretion ~22% (12% unchanged, 10% as metabolites). Minimal biliary excretion of unchanged drug. |
| Half-life | Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged in hepatic impairment (up to 3.1 hours). Clinically, it corrects within 2–4 hours after infusion cessation. |
| Protein binding | ~54% bound to human serum albumin (primarily) and α1-acid glycoprotein; binding is reversible and independent of concentration. |
| Volume of Distribution | 0.21–0.27 L/kg (7–9 L in 70 kg adult), suggesting distribution mainly in extracellular fluid; limited tissue penetration. |
| Bioavailability | Only available as intravenous infusion; oral bioavailability is negligible due to minimal gastrointestinal absorption. |
| Onset of Action | IV infusion: therapeutic anticoagulation (aPTT prolongation) occurs immediately upon achieving steady-state concentrations; bolus effect within minutes. |
| Duration of Action | Anticoagulant effect diminishes rapidly after infusion stop; aPTT returns to baseline within ~2–4 hours. Duration is dose- and infusion-rate dependent. |
Initial bolus of 350 mcg/kg IV over 3-5 minutes, followed by continuous IV infusion at 25 mcg/kg/min for normal coagulation; titrate to aPTT 1.5-3 times baseline, not exceeding 100 seconds; typical infusion rate 2-10 mcg/kg/min.
| Dosage form | SOLUTION |
| Renal impairment | No initial bolus reduction; infusion dose reduction recommended for CrCl <30 mL/min: start at 5 mcg/kg/min with aPTT monitoring; for CrCl 30-60 mL/min: start at 10 mcg/kg/min. |
| Liver impairment | Avoid use in patients with significant hepatic impairment (Child-Pugh Class B or C); if unavoidable, use with extreme caution and consider dose reduction by 50-75% based on aPTT response. |
| Pediatric use | Neonates and infants: initial bolus 50-100 mcg/kg IV, then infusion 0.1-0.5 mcg/kg/min; older children: initial bolus 350 mcg/kg IV, then infusion 25 mcg/kg/min; titrate to aPTT 1.5-2.5 times baseline. |
| Geriatric use | No specific dose adjustment solely for age; consider reduced initial infusion rate (15-20 mcg/kg/min) due to potential reduced renal function and increased bleeding risk; monitor aPTT closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARGATROBAN IN DEXTROSE (ARGATROBAN IN DEXTROSE).
| Breastfeeding | Excretion in human milk is unknown. Caution is advised. The M/P ratio is not available. Consider the importance of the drug to the mother and the potential risks to the nursing infant. |
| Teratogenic Risk | Argatroban is a pregnancy category B drug. No adequate controlled studies exist in pregnant women. In animal reproduction studies, no evidence of fetal harm was observed at intravenous doses up to 27 mg/kg/day (approximately 2.6 times the human dose of 10 mcg/kg/min based on body surface area). However, because animal studies are not always predictive of human response, use during pregnancy only if clearly needed. Risks to fetus during each trimester are not well-defined but are likely low based on limited human data. |
■ FDA Black Box Warning
Argatroban does not have a black box warning.
| Serious Effects |
["Active major bleeding","History of hypersensitivity to argatroban","Severe uncontrolled hypertension","Bacterial endocarditis"]
| Precautions | ["Risk of bleeding, especially in patients with major bleeding risk factors such as recent surgery, trauma, or severe hepatic impairment; dose adjustment required in hepatic impairment; monitor activated partial thromboplastin time (aPTT) closely; not recommended in neonates due to benzyl alcohol content; discontinuation may lead to thrombosis."] |
| Food/Dietary | Avoid excessive intake of vitamin K-rich foods (e.g., spinach, kale, broccoli, Brussels sprouts) as they can affect anticoagulation. No other specific dietary restrictions. |
Loading safety data…
| Fetal Monitoring | Monitor maternal coagulation parameters (aPTT, ACT) to maintain therapeutic levels (aPTT 1.5-3.0 times baseline). Monitor for bleeding signs, including placental abruption, in pregnant patients. Fetal monitoring as clinically indicated, such as nonstress test or biophysical profile, especially in high-risk pregnancies. |
| Fertility Effects | No specific human data on fertility effects. In animal studies, no adverse effects on fertility or reproductive performance were observed at intravenous doses up to 27 mg/kg/day. |
| Clinical Pearls | Monitor aPTT 2 hours after infusion initiation; adjust rate to achieve aPTT 1.5-3 times baseline. Contraindicated in patients with active major bleeding or history of heparin-induced thrombocytopenia (HIT) with argatroban use. Use with caution in hepatic impairment (reduce dose). Do not administer intramuscularly due to risk of hematoma. |
| Patient Advice | Report any signs of bleeding: unusual bruising, nosebleeds, blood in urine/stool, or coughing up blood. · Avoid activities with risk of injury (e.g., contact sports, using sharp objects). · Do not take any new medications (including aspirin, NSAIDs, or blood thinners) without consulting your doctor. · This medication is given intravenously; the infusion site should be monitored for redness or pain. |